AMTXBasic Materials · Specialty ChemicalsThe 4 Wall Street analysts covering Aemetis, Inc. hold a median 12-month price target of $12 — +858.3% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 50 of 100 as at 22 Oct 2026 — in the upper half.
Consensus tells you what everyone already believes. The model scores Aemetis, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Growth (95): Sales and profits are climbing, and climbing faster than before.
Issuance (8): The company has been issuing shares or taking on financing, diluting existing holders.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on AMTX, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +858.3% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 20 Aug 2026 | Ascendiant Capital | Maintains | Buy | $22 → $20 |
| 22 May 2026 | Ascendiant Capital | Maintains | Buy | $21 → $22 |
| 22 May 2026 | Ascendiant Capital | Maintains | Buy | — |
| 8 Apr 2026 | Ascendiant Capital | Maintains | Buy | — |
| 19 Nov 2025 | Ascendiant Capital | Maintains | Buy | — |
| 6 Oct 2025 | Ascendiant Capital | Maintains | Buy | — |
| 30 June 2025 | UBS | Maintains | Buy | — |
| 6 June 2025 | Ascendiant Capital | Maintains | Buy | — |
| 9 May 2025 | UBS | Maintains | Buy | — |
| 17 Mar 2025 | Ascendiant Capital | Maintains | Buy | — |
| 14 Mar 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 23 Dec 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 15 Nov 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 3 Sept 2024 | Ascendiant Capital | Maintains | Buy | — |
| 19 Aug 2024 | UBS | Maintains | Buy | — |
| 2 Aug 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 31 July 2024 | Truist Securities | Reiterates | Hold | — |
| 13 May 2024 | Truist Securities | Reiterates | Hold | — |
| 10 May 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 8 Mar 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
AMTX appears in the Radar on the weeks it earns a place.
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 22 Oct 2026, Aemetis, Inc. returned −53.8% against +15.6% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 83% of US stocks
Cheaper than 85% of US stocks
Cheaper than 93% of US stocks
Cheaper than 99% of US stocks
Higher than 69% of US stocks
Higher than 59% of US stocks
Higher than 23% of US stocks
Higher than 63% of US stocks
Higher than 14% of US stocks
Higher than 85% of US stocks
Higher than 35% of US stocks
Higher than 1% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Aemetis, Inc. has a market value of $91.7M and an enterprise value of $642.8M.
Revenue in the twelve months to 30 June 2026: $230.2M. The latest quarter grew 20.0% year on year.
Net income over the same four quarters: −$60.2M, a −26.1% net margin.
Diluted earnings per share, trailing twelve months: $−0.91.
Free cash flow in the twelve months to 30 June 2026: −$39.3M, after $35.7M of capital spending.
Trailing P/E: −1.0×; forward P/E: −2.5× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.00%, paying out 0% of earnings.
Aemetis, Inc. employs 220 people — $1.0M of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Aemetis, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Aemetis said its Biogas subsidiary completed construction and began operating two additional dairy biogas digesters in its biogas production network.
Why it matters — The announcement reports an expansion of Aemetis’ operating biogas infrastructure.
Options bears are circling Aemetis Inc (AMTX), along with Acadia Pharmaceuticals and Resideo Technologies, with puts handily outpacing calls in today's trading. The article highlights that put traders are targeting these three stocks.
Why it matters — Increased put activity suggests bearish sentiment among options traders regarding AMTX, which may signal market expectations for potential downside moves.
Aemetis, Inc. announced that it received $22.4 million from the sale of Section 45Z Clean Fuel Production Tax Credits. The payment was disclosed in a company news release dated September 28, 2026.
Why it matters — The cash inflow from monetizing clean fuel production tax credits provides Aemetis with additional liquidity, which is relevant for a watcher monitoring the company's financial position.
Stonegate Capital Partners updated its coverage of Aemetis Inc. following the company's 2Q26 results. Aemetis reported positive operating income driven by quarterly 45Z credit recognition, higher renewable natural gas production, and improved ethanol economics, which made the operating inflection visible.
Why it matters — This analyst update highlights that Aemetis' quarterly results turned to positive operating income, a milestone that AMTX watchers would track as evidence of improved financial performance.
Seeking Alpha published a transcript of Aemetis, Inc.'s (AMTX) Q2 2026 earnings call. The item announces the availability of the full earnings call transcript for the company's second-quarter 2026 results.
Why it matters — An AMTX watcher would care because the earnings call transcript provides management's discussion of the company's latest quarterly performance and outlook.
The 4 Wall Street analysts covering Aemetis, Inc. have a median 12-month price target of $12, with estimates ranging from $2.5 to $28. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 4 analysts covering Aemetis, Inc., 3 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Aemetis, Inc. 50 out of 100 across roughly 4,600 US stocks as at 22 Oct 2026. None of this is personal advice — it does not consider your circumstances.
As at 22 Oct 2026, Aemetis, Inc. ranks 50 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Growth (95 of 100).
No one can know that. What the data says: the median 12-month target from 4 analysts implies +858.3% from the last close, and Ticker Nerd's factor model ranks Aemetis, Inc. 50 out of 100 as at 22 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Aemetis, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for AMTX are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $2.5 to $28 over the next 12 months.
Aemetis, Inc. returned -53.8% over the 12 months to 22 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.
Aemetis Inc. is a renewable fuels and biochemicals company that develops and operates technologies designed to replace petroleum-based products with low- and negative-carbon alternatives.
The most recent item we track (MCAP MediaWire, 22 Oct 2026): "Aemetis Begins Operation of Two New Biogas Digesters". Aemetis said its Biogas subsidiary completed construction and began operating two additional dairy biogas digesters in its biogas production network.
Aemetis Inc. is a renewable fuels and biochemicals company that develops and operates technologies designed to replace petroleum-based products with low- and negative-carbon alternatives. The company focuses on producing renewable natural gas, ethanol, biodiesel, and related co-products used in transportation fuel, agricultural feed, and industrial applications. Its current operations span North America and India, with business segments centered on California Ethanol, California Dairy Renewable Natural Gas, and India Biodiesel. Aemetis also works on biogas capture, carbon reduction solutions, and the commercialization of advanced fuel and chemical processes. Headquartered in Cupertino, California, Aemetis serves markets tied to decarbonization, low-carbon fuel standards, and renewable energy supply chains.
CEO Mr. Eric A. McAfee · 220 employees · United States · https://www.aemetis.com
